Moreover, anti-MHC-I and anti-CD103 neutralizing antibodies dramatically inhibited target cell killing by autologous TIL pretreated with anti-PD-1, further emphasizing that CD8+CD103+ TRM cells were exhausted tumor-specific T lymphocytes, which could be rescued by blocking PD-1 signals resulting in T-cell activation and autologous tumor cell killing [27]. This evidence concerns the gene CD8A and neoplasm.